ReviewJournal of endocrinological investigation2026
"One-stop-shop" medical imaging for osteoporosis and obese patients: a narrative review.
Review in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity and osteoporosis frequently coexist. Assessing them separately can miss obesity-related bias in lumbar aBMD and fragility driven by impaired bone quality. To deliver a practical, scenario-based “one-stop-shop” that simultaneously characterizes adiposity and bone status.
methodsNarrative review framed by PICO. We searched the MEDLINE, PubMed, Scopus, and Web of Science databases to evaluate various imaging modalities for obesity and osteoporosis, as well as their feasibility for “one-stop-shop”.
resultsPathophysiologically, expansion of bone-marrow adipose tissue, adipokine/hormonal dysregulation, and mesenchymal stem-cell adipogenic shift, reduces bone mass. Clinically, the feasibility of mainstream imaging techniques for “one-stop-shop” is evaluated: As diagnostic tools, QCT and DXA cater precisely to the requirements of clinical diagnosis, providing reliable evidence for disease confirmation. As screening tools, both perform exceptionally well; among them, DXA, with its distinct advantages of lower radiation exposure and cost-effectiveness, is particularly suited for large-scale preliminary screening of populations. Additionally, DECT, MRI, and ultrasound can serve as effective supplementary tools, enhancing the comprehensive assessment of bone health and obesity.
conclusionsThis review focuses on the field of obesity-osteoporosis comorbidity. It deconstructs the interaction between the two conditions at the pathophysiological and clinical levels, explores the characteristics of high-risk populations, and examines the feasibility of the “one-stop-shop”. Bone mass and fat data acquired through “one-stop-shop” provide a more comprehensive and accurate reflection of adiposity and bone status, enabling clinicians to formulate targeted intervention strategies.
Indexed as
Identifiers
41999439What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.